Dupilumab
Indication
Treating moderate to severe prurigo nodularis (NICE TA955)
NICE TA955 - Dupilumab for treating moderate to severe prurigo nodularis
Black
Brand:
Dupixent
Nice TA:
955
Commissioning responsibility:
PbR excluded:
No
BNF chapter:
Skin
Background
1.1 Dupilumab is not recommended, within its marketing authorisation, for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: